IV Haloperidol (Haldol)

HaldolThe FDA has announced that the prescribing information for haloperidol (Haldol, generic versions) has been revised to include a new cardiovascular subsection in the Warnings section.

Life-threatening generic arrhythmias (e.g., sudden death, QT prolongation, torsades de pointes) have been reported in patients treated with haloperidol, especially when the drug is administered intravenously or at doses higher than recommended.

Injectable haloperidol is approved only for intramuscular injection, although IV administration is known to be a fairly common off-label clinical practice. A minimum of 28 cases of QT prolongation and torsades de pointes have been reported following intravenous administration, and some have resulted in death.

(Sources: FDA)